Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selumetinib in Advanced or Metastatic Hepatocellular Carcinoma
NCT00604721Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Nov 2007
- Primary completion
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of selumetinib in hepatocellular carcinoma (HCC), sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate at 33 weeks. Started Nov 2007; status: completed.
02
Drugs
selumetinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00604721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00604721.